Amgen

Amgen Inc. on April 27 said the U.S. Internal Revenue Service (IRS) is seeking additional back taxes of $5.1 billion, plus interest and penalties, related to the drugmaker’s 2013 to 2015 accounting for profits between the United States and Puerto Rico, the location of most of the company’s manufacturing operations.

Sanofi

Sanofi plans to list the company’s drug ingredients subsidiary EUROAPI on May 6, saying the business is set to grow and improve its profitability as a separate business.

Japan’s Eisai Co. Ltd. will surrender the company’s rights to share profit from Aduhelm – the Alzheimer’s treatment drug jointly developed with U.S. partner Biogen Inc. – and instead receive sales royalties, the companies said on March 14.

Chicago-based AbbVie has been making major decisions with company-wide impacts that could benefit its bottom line. 

Abbott

Abbott Laboratories beat fourth-quarter 2021 profit and sales estimates, aided by robust sales of COVID-19 test kits and strong demand for the company’s diagnostics products, but forecast lower-than-expected COVID-19 testing sales in 2022 due to uncertainties around the future of the pandemic.

AstraZeneca reported Covid-19 vaccine sales of $1.05 billion for third-quarter 2021, with Vaxzevria contributing 1 percent to the company’s profit for the quarter.

AbbVie Inc. on Oct. 29 raised the company’s 2021 adjusted profit forecast for the third time this year after a stellar performance by newer medicines helped the U.S. drugmaker beat Wall Street estimates for third-quarter profit and revenue.

Bristol Myers Squibb Co. reported lower-than-expected first-quarter profit on April 29 as sales of the company’s high margin cancer drugs Revlimid and Opdivo fell short of Wall Street estimates.